ClinicalTrials.gg
CompletedNCT00922207Updated Apr 10, 2017Results posted

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

A Phase 4 interventional study of Adefovir and Entecavir in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 9 sites in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-10.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing adefovir in Hepatitis B, Chronic — none open to participants now, none under way, none of them phase 3. adefovir · Hepatitis B, Chronic.

Enrollment
12th of 28
280 · median 164
Started
2010
with 2 others
Phase 4
19 of 29
none open now
Registered
17th of 29
by date
Lead sponsor
2 of 29
Hoffmann-La Roche

Among the 29 studies testing adefovir in Hepatitis B, Chronic, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2010, is one of 19 in phase 4, and was the 17th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 29 studies testing adefovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About adefovir

adefovir: first FDA approval 2002 (HEPSERA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing adefovir in Hepatitis B, Chronic as a file.
02

Study summary

This 3 arm study will assess the efficacy and safety of PEGASYS alone, or in combination with Adefovir or Entecavir in patients with HBeAg positive chronic hepatitis B. Patients will be randomized to receive 1)PEGASYS 180 micrograms sc weekly for 48 weeks + placebo from weeks -4 to 2;2)PEGASYS 180 micrograms sc weekly for 48 weeks + Adefovir from weeks -4 to 2; or 3)PEGASYS 180 micrograms sc weekly for 48 weeks + Entecavir from weeks -4 to 2. Treatment will be followed by 24 weeks of treatment-free follow-up.The anticipated time on study treatment is 1 year, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-65 years of age;
  • HBeAg+ve for >=3 months;
  • positive serum within 3 months prior to entry;
  • patients with chronic hepatitis B, either naive to HBV treatment, or not responded/ to nucleoside analogues;
  • >=3 months treatment-free interval from nucleotide analogues.

Exclusion criteria

Exclusion Criteria:

  • evidence of decompensated liver disease;
  • history or other evidence of a medical condition associated with chronic liver disease othr than viral hepatitis;
  • co-infection with active hepatitis A,C or D, or .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    1

    Drug: Adefovir · Drug: peginterferon alfa-2a [Pegasys]

  • Experimental
    2

    Drug: Entecavir · Drug: peginterferon alfa-2a [Pegasys]

  • Placebo comparator
    3

    Drug: Placebo · Drug: peginterferon alfa-2a [Pegasys]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment

    HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of hepatitis B e-antibody (anti-HBe/HBeAb) (a positive result for anti-HBe).

    Time frame: Week 100

Secondary outcomes

  1. Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

    HBV DNA (copies per milliliter \[copies/mL\]) represented the viral load for Hepatitis B Virus (HBV), and was considered an indicator of viral replication.

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

  2. Percentage of Participants Who Were HBeAg Negative

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

  3. Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

  4. Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels

    The normal range for ALT is 10 to 40 international units per liter (IU/L).

    Time frame: Baseline, Weeks 6, 12, 16, 22, 28, 34, 40, 46, 52, 64, 76, 88, and 100

  5. Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

  6. Percentage of Participants With Combined Response

    Combined response was defined as having negative HBeAg, HBV DNA less than (\<) 100,000 copies/mL, and normal ALT level (10-40 IU/L).

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

07

Results

Posted Nov 20, 2015

Participant flow

Participant flow — Overall Study
MilestonePeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Started919594
Completed858890
Not completed674
Withdrew: Adverse event/intercurrent illness300
Withdrew: Insufficient therapeutic response001
Withdrew: Violation of selection criteria at entry010
Withdrew: Refused treatment/did not cooperate100
Withdrew: Withdrew consent252
Withdrew: Abnormality of laboratory test011

Outcome measures

PrimaryPercentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment

HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of hepatitis B e-antibody (anti-HBe/HBeAb) (a positive result for anti-HBe).

Time frame:
Week 100
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment
percentage of participantsPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment27.4 (17.8 to 36.9)29.5 (20.0 to 39.1)36.3 (26.4 to 46.1)
Statistical analysis
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.6853 · Odds ratio (or): 0.90 · 95% CI 0.46 to 1.75
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.1977 · Odds ratio (or): 0.66 · 95% CI 0.35 to 1.26
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2916 · Odds ratio (or): 0.74 · 95% CI 0.39 to 1.38
SecondaryChange From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100

HBV DNA (copies per milliliter \[copies/mL\]) represented the viral load for Hepatitis B Virus (HBV), and was considered an indicator of viral replication.

Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Reported as:
Mean · copies/mL
Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
copies/mLPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Baseline (n=91,95,94)8.65 ± 1.038.30 ± 1.218.41 ± 0.96
Change at Week 4 (n=90,94,92)-2.15 ± 0.94-2.76 ± 0.97-0.23 ± 0.88
Change at Week 8 (n=90,94,92)-1.87 ± 1.40-3.58 ± 1.12-1.32 ± 1.32
Change at Week 16 (n=90,94,92)-2.14 ± 1.72-3.77 ± 1.53-2.13 ± 1.93
Change at Week 28 (n=90,94,92)-2.34 ± 1.90-3.07 ± 1.88-2.84 ± 2.14
Change at Week 40 (n=90,94,92)-2.61 ± 2.11-2.97 ± 2.11-3.27 ± 2.25
Change at Week 52 (n=90,94,92)-2.75 ± 2.29-2.81 ± 2.43-3.32 ± 2.48
Change at Week 64 (n=90,94,92)-1.87 ± 2.26-1.37 ± 2.31-2.11 ± 2.42
Change at Week 76 (n=90,94,92)-1.91 ± 2.24-1.39 ± 2.46-2.20 ± 2.57
Change at Week 88 (n=90,94,92)-1.78 ± 2.36-1.39 ± 2.42-2.30 ± 2.34
Change at Week 100 (n=90,94,92)-2.00 ± 2.35-1.78 ± 2.41-2.17 ± 2.44
Statistical analysis
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.0353 · Least squares (ls) mean difference: 0.34 · 95% CI 0.02 to 0.66
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.1114 · Ls mean difference: 0.23 · 95% CI -0.05 to 0.52
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5150 · Ls mean difference: -0.10 · 95% CI -0.42 to 0.21
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = <0.001 · Ls mean difference: 0.62 · 95% CI 0.34 to 0.89
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.92 · 95% CI -2.19 to -1.65
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = <0.001 · Ls mean difference: -2.54 · 95% CI -2.81 to -2.27
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = <0.001 · Ls mean difference: 1.70 · 95% CI 1.34 to 2.06
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0071 · Ls mean difference: -0.55 · 95% CI -0.95 to -0.15
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = <0.001 · Ls mean difference: -2.26 · 95% CI -2.61 to -1.90
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = <0.001 · Ls mean difference: 1.62 · 95% CI 1.16 to 2.08
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.9557 · Ls mean difference: -0.02 · 95% CI -0.56 to 0.53
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.65 · 95% CI -2.15 to -1.14
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.0094 · Ls mean difference: 0.73 · 95% CI 0.18 to 1.27
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0943 · Ls mean difference: 0.51 · 95% CI -0.09 to 1.11
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.4354 · Ls mean difference: -0.23 · 95% CI -0.82 to 0.35
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.2509 · Ls mean difference: 0.36 · 95% CI -0.26 to 0.98
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0429 · Ls mean difference: 0.67 · 95% CI 0.02 to 1.31
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.3585 · Ls mean difference: 0.30 · 95% CI -0.34 to 0.93
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.9014 · Ls mean difference: 0.04 · 95% CI -0.65 to 0.74
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.1122 · Ls mean difference: 0.57 · 95% CI -0.13 to 1.28
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.1602 · Ls mean difference: 0.51 · 95% CI -0.20 to 1.23
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.1599 · Ls mean difference: -0.49 · 95% CI -1.17 to 0.19
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5045 · Ls mean difference: 0.23 · 95% CI -0.45 to 0.92
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0412 · Ls mean difference: 0.72 · 95% CI 0.03 to 1.41
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.1347 · Ls mean difference: -0.54 · 95% CI -1.24 to 0.17
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.4027 · Ls mean difference: 0.30 · 95% CI -0.41 to 1.01
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0311 · Ls mean difference: 0.81 · 95% CI 0.07 to 1.55
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.3183 · Ls mean difference: -0.36 · 95% CI -1.07 to 0.35
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.1371 · Ls mean difference: 0.52 · 95% CI -0.17 to 1.22
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0113 · Ls mean difference: 0.90 · 95% CI 0.21 to 1.60
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5608 · Ls mean difference: -0.21 · 95% CI -0.92 to 0.50
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.6323 · Ls mean difference: 0.17 · 95% CI -0.53 to 0.88
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.2752 · Ls mean difference: 0.40 · 95% CI -0.32 to 1.11
SecondaryPercentage of Participants Who Were HBeAg Negative
Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Were HBeAg Negative
percentage of participantsPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Baseline (n=91,95,94)3.3 (0.0 to 7.0)2.1 (0.0 to 5.0)0.0 (NA to NA)
Week 4 (n=90,94,92)5.6 (0.8 to 10.3)4.3 (0.2 to 8.3)1.1 (0.0 to 3.2)
Week 8 (n=90,94,92)6.7 (1.5 to 11.8)6.4 (1.4 to 11.3)4.3 (0.2 to 8.5)
Week 16 (n=90,94,92)6.7 (1.5 to 11.8)8.5 (2.9 to 14.2)10.9 (4.5 to 17.2)
Week 28 (n=90,94,92)11.1 (4.6 to 17.6)10.6 (4.4 to 16.9)16.3 (8.8 to 23.9)
Week 40 (n=90,94,92)18.9 (10.8 to 27.0)18.1 (10.3 to 25.9)22.8 (14.2 to 31.4)
Week 52 (n=90,94,92)22.2 (13.6 to 30.8)22.3 (13.9 to 30.8)29.3 (20.0 to 38.7)
Week 64 (n=90,92,92)24.4 (15.6 to 33.3)25.0 (16.2 to 33.8)31.5 (22.0 to 41.0)
Week 76 (n=88,88,92)25.0 (16.0 to 34.0)28.4 (19.0 to 37.8)37.0 (27.1 to 46.8)
Week 88 (n=86,87,90)27.9 (18.4 to 37.4)27.6 (18.2 to 37.0)34.4 (24.6 to 44.3)
Week 100 (n=84,87,91)28.6 (18.9 to 38.2)32.2 (22.4 to 42.0)37.4 (27.4 to 47.3)
Statistical analysis
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.6107 · Odds ratio (or): 1.59 · 95% CI 0.26 to 9.71
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0788
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.1761
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.7044 · Odds ratio (or): 1.32 · 95% CI 0.34 to 5.09
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0927 · Odds ratio (or): 5.35 · 95% CI 0.61 to 46.76
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.1858 · Odds ratio (or): 4.04 · 95% CI 0.44 to 36.89
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.9385 · Odds ratio (or): 1.05 · 95% CI 0.33 to 3.38
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.5068 · Odds ratio (or): 1.57 · 95% CI 0.43 to 5.77
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.5544 · Odds ratio (or): 1.50 · 95% CI 0.41 to 5.50
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.6510 · Odds ratio (or): 0.77 · 95% CI 0.26 to 2.31
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3192 · Odds ratio (or): 0.59 · 95% CI 0.20 to 1.69
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.5818 · Odds ratio (or): 0.76 · 95% CI 0.29 to 2.03
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.8796 · Odds ratio (or): 1.05 · 95% CI 0.41 to 2.66
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3050 · Odds ratio (or): 0.64 · 95% CI 0.27 to 1.52
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2414 · Odds ratio (or): 0.61 · 95% CI 0.26 to 1.44
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.8502 · Odds ratio (or): 1.05 · 95% CI 0.50 to 2.22
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.5000 · Odds ratio (or): 0.79 · 95% CI 0.38 to 1.61
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3882 · Odds ratio (or): 0.75 · 95% CI 0.36 to 1.53
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.9584 · Odds ratio (or): 0.99 · 95% CI 0.50 to 1.99
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2576 · Odds ratio (or): 0.69 · 95% CI 0.35 to 1.34
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2362 · Odds ratio (or): 0.69 · 95% CI 0.36 to 1.34
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.9861 · Odds ratio (or): 0.97 · 95% CI 0.49 to 1.90
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2919 · Odds ratio (or): 0.70 · 95% CI 0.37 to 1.35
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2674 · Odds ratio (or): 0.72 · 95% CI 0.38 to 1.38
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.6148 · Odds ratio (or): 0.84 · 95% CI 0.43 to 1.64
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0904 · Odds ratio (or): 0.57 · 95% CI 0.30 to 1.08
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2073 · Odds ratio (or): 0.68 · 95% CI 0.36 to 1.27
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.9980 · Odds ratio (or): 1.02 · 95% CI 0.52 to 1.98
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3489 · Odds ratio (or): 0.74 · 95% CI 0.39 to 1.40
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2847 · Odds ratio (or): 0.73 · 95% CI 0.38 to 1.38
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.5596 · Odds ratio (or): 0.84 · 95% CI 0.44 to 1.62
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2112 · Odds ratio (or): 0.67 · 95% CI 0.36 to 1.27
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.4066 · Odds ratio (or): 0.80 · 95% CI 0.43 to 1.48
SecondaryPercentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive
Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Reported as:
Number · percentage of participants
Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive
percentage of participantsPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Baseline (n=91,95,94)0.00.00.0
Week 4 (n=90,94,92)0.00.00.0
Week 8 (n=90,94,92)0.00.00.0
Week 16 (n=90,94,92)0.00.00.0
Week 28 (n=90,94,92)0.00.00.0
Week 40 (n=90,94,92)0.00.00.0
Week 52 (n=90,94,92)0.00.00.0
Week 64 (n=90,92,92)0.00.00.0
Week 76 (n=88,88,92)0.00.00.0
Week 88 (n=86,87,90)1.20.03.4
Week 100 (n=84,87,91)0.00.00.0
SecondaryPercentage of Participant With Normal Alanine Aminotransferase (ALT) Levels

The normal range for ALT is 10 to 40 international units per liter (IU/L).

Time frame:
Baseline, Weeks 6, 12, 16, 22, 28, 34, 40, 46, 52, 64, 76, 88, and 100
Reported as:
Number · percentage of participants
Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels
percentage of participantsPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Baseline (n=91,95,94)4.43.22.1
Week 6 (n=90,93,92)4.45.46.5
Week 12 (n=90,93,92)15.617.213.0
Week 16 (n=90,93,92)21.124.720.7
Week 22 (n=90,93,92)25.634.422.8
Week 28 (n=90,93,92)26.730.123.9
Week 34 (n=90,93,92)26.734.432.6
Week 40 (n=90,93,92)30.039.832.6
Week 46 (n=90,93,92)30.041.933.7
Week 52 (n=90,93,92)33.334.432.6
Week 64 (n=90,92,92)32.237.042.4
Week 76 (n=89,89,92)43.838.246.7
Week 88 (n=86,88,91)32.633.048.4
Week 100 (n=84,88,91)36.940.949.5
Statistical analysis
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.6921 · Odds ratio (or): 1.41
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3939 · Odds ratio (or): 2.11
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.6818 · Odds ratio (or): 1.50
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.7582 · Odds ratio (or): 0.82
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.5381 · Odds ratio (or): 0.67
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.7747 · Odds ratio (or): 0.81
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.8034 · Odds ratio (or): 0.89
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.6306 · Odds ratio (or): 1.23
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.4574 · Odds ratio (or): 1.39
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.5824 · Odds ratio (or): 0.81
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.9321 · Odds ratio (or): 1.03
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.5263 · Odds ratio (or): 1.26
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.2025 · Odds ratio (or): 0.65
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.6702 · Odds ratio (or): 1.16
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0818 · Odds ratio (or): 1.77
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.6214 · Odds ratio (or): 0.84
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.6774 · Odds ratio (or): 1.16
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3154 · Odds ratio (or): 1.37
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.2709 · Odds ratio (or): 0.69
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3804 · Odds ratio (or): 0.75
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.7645 · Odds ratio (or): 1.08
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.1820 · Odds ratio (or): 0.65
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.7167 · Odds ratio (or): 0.89
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.3104 · Odds ratio (or): 1.37
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.0910 · Odds ratio (or): 0.59
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.6094 · Odds ratio (or): 0.84
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2166 · Odds ratio (or): 1.42
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.9010 · Odds ratio (or): 0.95
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.9060 · Odds ratio (or): 1.03
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.7268 · Odds ratio (or): 1.08
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.5372 · Odds ratio (or): 0.81
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.1588 · Odds ratio (or): 0.65
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.4268 · Odds ratio (or): 0.80
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.4389 · Odds ratio (or): 1.26
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.6708 · Odds ratio (or): 0.89
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2145 · Odds ratio (or): 0.70
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.8608 · Odds ratio (or): 0.98
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0283 · Odds ratio (or): 0.52
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0369 · Odds ratio (or): 0.53
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · Cochran-Mantel-Haenszel · p = 0.4606 · Odds ratio (or): 0.84
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.0832 · Odds ratio (or): 0.60
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · Cochran-Mantel-Haenszel · p = 0.2655 · Odds ratio (or): 0.71
SecondaryChange From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Reported as:
Mean · International Units/milliliter (IU/mL)
Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
International Units/milliliter (IU/mL)Peg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Baseline (n=91,95,94)3.97 ± 0.723.76 ± 0.833.84 ± 0.71
Change at Week 4 (n=90,94,92)-0.26 ± 0.48-0.18 ± 0.44-0.02 ± 0.33
Change at Week 8 (n=90,94,92)-0.33 ± 0.78-0.31 ± 0.58-0.25 ± 0.56
Change at Week 16 (n=90,94,92)-0.40 ± 0.78-0.49 ± 0.74-0.48 ± 0.83
Change at Week 28 (n=90,94,92)-0.61 ± 0.96-0.68 ± 0.98-0.70 ± 1.08
Change at Week 40 (n=90,94,92)-0.71 ± 1.09-0.67 ± 1.04-0.82 ± 1.27
Change at Week 52 (n=90,94,92)-0.78 ± 1.27-0.69 ± 1.11-0.88 ± 1.41
Change at Week 64 (n=90,94,92)-0.67 ± 1.18-0.54 ± 1.07-0.67 ± 1.21
Change at Week 76 (n=90,94,92)-0.58 ± 0.95-0.45 ± 1.01-0.53 ± 1.19
Change at Week 88 (n=90,94,92)-0.50 ± 1.11-0.44 ± 0.90-0.62 ± 1.20
Change at Week 100 (n=90,94,92)-0.41 ± 0.75-0.60 ± 1.15-0.56 ± 1.10
Statistical analysis
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.0649 · Ls mean difference: 0.21 · 95% CI -0.01 to 0.43
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.1867 · Ls mean difference: 0.13 · 95% CI -0.06 to 0.33
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5003 · Ls mean difference: -0.08 · 95% CI -0.30 to 0.15
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.2259 · Ls mean difference: -0.08 · 95% CI -0.22 to 0.05
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = <0.001 · Ls mean difference: -0.24 · 95% CI -0.36 to -0.11
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.0085 · Ls mean difference: -0.15 · 95% CI -0.27 to -0.04
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.8160 · Ls mean difference: -0.02 · 95% CI -0.22 to 0.18
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.4393 · Ls mean difference: -0.08 · 95% CI -0.27 to 0.12
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.4890 · Ls mean difference: -0.06 · 95% CI -0.22 to 0.11
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.4656 · Ls mean difference: 0.08 · 95% CI -0.14 to 0.30
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5016 · Ls mean difference: 0.08 · 95% CI -0.15 to 0.31
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.9582 · Ls mean difference: -0.01 · 95% CI -0.23 to 0.22
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.6214 · Ls mean difference: 0.07 · 95% CI -0.21 to 0.36
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5493 · Ls mean difference: 0.09 · 95% CI -0.21 to 0.39
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.8881 · Ls mean difference: 0.02 · 95% CI -0.28 to 0.32
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.7912 · Ls mean difference: -0.04 · 95% CI -0.36 to 0.27
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.5427 · Ls mean difference: 0.11 · 95% CI -0.24 to 0.46
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.3788 · Ls mean difference: 0.15 · 95% CI -0.19 to 0.49
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.6172 · Ls mean difference: -0.09 · 95% CI -0.44 to 0.26
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.6002 · Ls mean difference: 0.11 · 95% CI -0.29 to 0.50
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.3101 · Ls mean difference: 0.19 · 95% CI -0.18 to 0.56
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.4256 · Ls mean difference: -0.14 · 95% CI -0.47 to 0.20
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.9762 · Ls mean difference: 0.01 · 95% CI -0.35 to 0.36
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.4504 · Ls mean difference: 0.13 · 95% CI -0.21 to 0.47
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.4076 · Ls mean difference: -0.12 · 95% CI -0.42 to 0.17
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.7591 · Ls mean difference: -0.05 · 95% CI -0.37 to 0.27
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.6449 · Ls mean difference: 0.08 · 95% CI -0.25 to 0.40
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.7108 · Ls mean difference: -0.06 · 95% CI -0.36 to 0.25
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.4725 · Ls mean difference: 0.12 · 95% CI -0.22 to 0.47
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.2439 · Ls mean difference: 0.19 · 95% CI -0.13 to 0.50
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Entecavir · ANCOVA · p = 0.1862 · Ls mean difference: 0.20 · 95% CI -0.10 to 0.50
  • Peg-IFN-Alfa-2a + Adefovir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.3057 · Ls mean difference: 0.15 · 95% CI -0.14 to 0.43
  • Peg-IFN-Alfa-2a + Entecavir vs Peg-IFN-Alfa-2a + Placebo · ANCOVA · p = 0.8002 · Ls mean difference: -0.04 · 95% CI -0.38 to 0.29
SecondaryPercentage of Participants With Combined Response

Combined response was defined as having negative HBeAg, HBV DNA less than (\<) 100,000 copies/mL, and normal ALT level (10-40 IU/L).

Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Reported as:
Number · percentage of participants
Percentage of Participants With Combined Response
percentage of participantsPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
Baseline (n=91,95,94)0.00.00.0
Week 16 (n=90,93,92)0.00.00.0
Week 28 (n=90,93,92)0.01.10.0
Week 40 (n=90,93,92)0.00.00.0
Week 52 (n=90,93,92)0.00.00.0
Week 64 (n=90,92,92)2.20.00.0
Week 76 (n=88,89,92)3.40.00.0
Week 88 (n=86,88,91)3.50.00.0
Week 100 (n=84,88,91)2.40.00.0

Adverse events

Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peg-IFN-Alfa-2a + Adefovir—7/91 (7.7%)85/91 (93.4%)
Peg-IFN-Alfa-2a + Entecavir—12/94 (12.8%)83/94 (88.3%)
Peg-IFN-Alfa-2a + Placebo—7/93 (7.5%)89/93 (95.7%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
OverdoseInjury, poisoning and procedural complications1/914/941/93
Hepatitis BInfections and infestations2/910/940/93
Hepatic failureHepatobiliary disorders1/910/940/93
CellulitisInfections and infestations1/910/940/93
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/910/940/93
Calculus urethralRenal and urinary disorders1/910/940/93
Upper gastrointestinal heamorrhageGastrointestinal disorders1/910/940/93
HepatitisHepatobiliary disorders0/911/941/93
Peritonsillar abscessInfections and infestations0/910/941/93
Urinary tract infectionInfections and infestations0/910/941/93
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPeg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + Placebo
AlopeciaSkin and subcutaneous tissue disorders23/9127/9425/93
HeadacheNervous system disorders21/9117/9420/93
PyrexiaGeneral disorders20/9119/9421/93
Alanine aminotransferase increasedInvestigations14/9117/9418/93
MyalgiaMusculoskeletal and connective tissue disorders17/9113/9418/93
FatigueGeneral disorders13/9112/9415/93
PruritisSkin and subcutaneous tissue disorders11/9114/9415/93
DiarrhoeaGastrointestinal disorders14/919/9413/93
Upper respiratory tract infectionInfections and infestations6/9111/9414/93
DizzinessNervous system disorders8/9114/948/93

Baseline characteristics

Intent-to-treat (ITT) analysis population included all randomized participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Peg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + PlaceboTotal
Mean38.7 ± 9.737.7 ± 10.038.2 ± 9.738.2 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Peg-IFN-Alfa-2a + AdefovirPeg-IFN-Alfa-2a + EntecavirPeg-IFN-Alfa-2a + PlaceboTotal
Female25282881
Male666766199
08

Study locations

9 sites
  • Changhua Christian Hospital; Internal Medicine
    Changhua, 500, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine
    Kaohsiung, 00833, Taiwan
  • Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine
    Kaohsiung, 807, Taiwan
  • Chang Gung Medical Foundation - Keelung; Dept. of Hepato-Gastroenterology
    Keelung City, 204, Taiwan
  • China Medical University Hospital; Department of Rheumatology
    Taichung, 404, Taiwan
  • National Taiwan Uni Hospital; Gastro-Enterology Dept.
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital; Gastroenterology Division
    Taipei, 112, Taiwan
  • Tri-Service Hospital; Dept. of Internal Medicine
    Taipei, Taiwan
  • Chang Gung Medical Foundation - Linkou; Dept. of Hepato-Gastroenterology
    Taoyuan, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Sep 2014, 52 months.

Results were first posted in Nov 2015, 1 year 1 month after primary completion.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2009
First posted
Jun 17, 2009
StartActual
May 7, 2010
Primary completionActual
Sep 29, 2014
CompletionActual
Sep 29, 2014
Results first posted
Nov 20, 2015
Last update
Apr 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00922207
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 17, 2009
Start date
May 7, 2010
Primary completion
Sep 29, 2014
Completion
Sep 29, 2014
Results posted
Nov 20, 2015
Last update
Apr 10, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adefovir · Entecavir

Start the discussion